[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Northside Hospital, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":201},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,44,68,87,106,122,139,158,180],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100642651",false,"NCT07638982","Axatilimab + CAR-T for High-Risk Lymphoma","An Open-label, Phase I Trial, With an Expansion Cohort: Macrophage Conditioning to Synergize With CAR-T in High-risk Lymphoma (MAC-SHIFT)","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Histologically confirmed large B-cell lymphoma\n* Presence of one or more high-risk features\n* Eligible to receive CAR-T according to the FDA label\n* Measurable disease by CT or PET\n* Adequate organ function unless related to lymphoma involvement:\n* Pulse oximetry ≥ 92% on room air\n* Ejection Fraction ≥ 40%\n* ALT\u002FAST \\\u003C 5x ULN\n* Bilirubin \\\u003C 3 x ULN\n* Calculated or measured creatinine Clearance ≥ 30 mL\u002Fmin\n\nExclusion Criteria:\n\n* KPS \\\u003C60\n* Second malignancy with a high metastatic potential within 3 years\n* Active CNS involvement. Treated CNS disease is allowed\n* Active HBV or HCV infection.\n* Active uncontrolled infections\n* Known HIV positive status\n* Allogeneic transplant within 100 days of enrollment\n* Active acute or chronic graft versus host disease\n* History of acute or chronic pancreatitis\n* History of myositis","ALL","8 Years",{"count":18,"type":19},29,"ESTIMATED","INTERVENTIONAL",[22],"PHASE1","Axatilimab + CAR-T in High-Risk Lymphoma",[25,26,27,28,29,30],"Diffuse Large B Cell Lymphoma (DLBCL)","Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma","High-grade B-cell Lymphoma (HGBCL)","High-Grade B-Cell Lymphoma, Nos","PMBCL","Follicular Grade 3 Lymphoma","NOT_YET_RECRUITING","2026-06-05",{"date":34,"type":35},"2026-06-10","ACTUAL",{"date":37,"type":19},"2026-10-31",{"date":39,"type":19},"2029-12-31",{"name":41,"class":42},"Northside Hospital, Inc.","OTHER",1,{"id":45,"slug":4,"hasResults":10,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":10,"sex":15,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":20,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":43},"100579784","NCT06828796","Early Use of Tacrolimus in HLA-Mismatched Haploidentical Allogeneic Hematopoietic Transplantation With Post-Transplant Cyclophosphamide","Inclusion Criteria:\n\n* Availability of a 5\u002F10-8\u002F10 mismatched (HLA-A, B, DR) haploidentical related donor with a negative HLA cross-match in the host vs. graft direction and willing to provide peripheral blood stem cells\n* Karnofsky status \\>\u002F= 70%\n* Hematologic malignancy requiring allogeneic transplantation\n* First allogeneic transplant only. Prior autologous transplant is allowed.\n\nExclusion Criteria:\n\n* Poor cardiac function: LVEF \\\u003C40%\n* Poor pulmonary function: FEV1 and FVC \\\u003C50% predicted\n* Poor liver function: bilirubin \\>\u002F= 3mg\u002FdL (not due to hemolysis, Gilbert's or primary malignancy)\n* Poor renal function: Creatinine \\>\u002F= 2mg\u002FdL or creatinine clearance (calculated or measured creatinine clearance is permitted) \\\u003C40mL\u002Fmin based on Traditional Cockcroft-Gault formula\n* Women of childbearing potential who currently are pregnant or who are not practicing adequate contraception\n* Patients who have any debilitating medical or psychiatric illness that would preclude their giving informed consent or their receiving optimal treatment and follow up","18 Years","80 Years",{"count":52,"type":19},20,[54],"PHASE2","To evalute the safety and efficacy in reducing Cytokine Release Syndrome after hematopoietic stem cell transplantation by introducing immunosuppression earlier in the transplant process",[57,58],"Hematologic Disease and Disorders","Hematopoietic Cell Transplant","RECRUITING","2026-04-15",{"date":62,"type":35},"2026-04-16",{"date":64,"type":35},"2025-07-03",{"date":66,"type":19},"2028-06-30",{"name":41,"class":42},{"id":69,"slug":4,"hasResults":10,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":10,"sex":15,"minAge":49,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":20,"phases":76,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":43},"100519645","NCT06046248","Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease","Phase II Trial of Belumosudil and Rituximab for the Primary Treatment of Extensive Chronic Graft-versus-host Disease","Inclusion Criteria:\n\n* First episode of systemic immunosuppression-requiring cGVHD, defined as classic cGVHD by the NIH consensus criteria (without features or characteristics of aGVHD)\n* Previously untreated, defined by having received \\\u003C10 days of corticosteroids or alternative systemic immunosuppressive agent started specifically for a new diagnosis of cGVHD\n* KPS \\>\u002F= 70%\n* Adequate hematologic function independent of platelet transfusion and G-CSF for at least 7 days prior to study entry: ANC \\>750 cells\u002Fmm3; Platelets \\>30,000 cells\u002Fmm#\n\nExclusion Criteria:\n\n* Late persistent or recurrent aGVHD\n* Active uncontrolled infection\n* History of HIV infection\n* Active HBV or HCV infection. Subjects who are positive for hepatitis B core antibody, hepatitis B surface antigen, or hepatitis C antibody must have a negative PCR result before enrollment. Those who are PCR positive will be excluded.\n* Calculated CrCl \\\u003C30mL\u002Fmin\n* AST and\u002For ALT \\>5x ULN or direct bilirubin \\>3x ULN\n* Cardiac ejection fraction \\\u003C40% or history of uncontrolled cardiac arrhythmias\n* Has received more than one allogeneic transplant prior to the occurrence of cGVHD",{"count":75,"type":19},25,[54],"This is an open-label, Phase 2 study designed to evaluate the safety and efficacy of belumosudil and rituximab as primary treatment of cGVHD.",[79],"Chronic Graft Versus Host Disease",{"date":81,"type":35},"2026-04-20",{"date":83,"type":35},"2024-01-29",{"date":85,"type":19},"2027-12-31",{"name":41,"class":42},{"id":88,"slug":4,"hasResults":10,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":10,"sex":15,"minAge":49,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":20,"phases":94,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":100,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":43},"100509102","NCT05909059","CAR T-cell Therapy in Patients With Renal Dysfunction","Lymphodepleting Chemotherapy With Fludarabine and Cyclophosphamide Prior to Infusion of CAR T Cell Therapy in Patients With Moderate-Severe Renal Dysfunction","Inclusion Criteria:\n\n* Receiving lymphodepleting chemotherapy prior to commercial CAR-T administration for multiple myeloma, leukemia, or lymphoma\n* Adequate bone marrow function to receive lymphodepleting chemotherapy\n* Renal function \\\u003C\u002F= 60mL\u002Fmin\u002F1.73m2\n* ECOG 0-2\n\nExclusion Criteria:\n\n* Relative CNS disorders\n* Active uncontrolled infection or any other concurrent disease or medical condition that was deemed to interfere with the conduct of the study as judged by the investigator\n* Use of therapeutic dose systemic corticosteroids (defined as \\>20mg\u002Fday prednisone or equivalent) within 72 hours of CAR-T administration",{"count":52,"type":19},[54],"This is a prospective, descriptive study designed to assess the feasibility of administering CAR T therapy among patients with moderate to severe renal impairment using dose adjusted lymphodepleting chemotherapy.",[97,98,99],"Non-hodgkin Lymphoma,B Cell","Multiple Myeloma","Acute Lymphoblastic Leukemia, Adult",{"date":81,"type":35},{"date":102,"type":35},"2024-11-18",{"date":104,"type":19},"2027-08-31",{"name":41,"class":42},{"id":107,"slug":4,"hasResults":10,"nctId":108,"briefTitle":109,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":10,"sex":15,"minAge":49,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":20,"phases":112,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":116,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":43},"100479176","NCT05519579","Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia","Inclusion Criteria:\n\n* Adults receiving first cycle of blinatumomab for relapse\u002Frefractory or MRD-positive B-cell Acute Lymphoblastic Leukemia\n* Adequate renal and hepatic function\n* Negative for HIV\n* Negative serum pregnancy test, if applicable\n* ECOG 0-2\n\nExclusion Criteria:\n\n* Active CNS involvement by ALL\n* Relative CNS disorders (seizure, paresis, aphasia, Cerebrovascular ischemia\u002Fhemorrhage, severe brain injury, dementia, Parkinson's, cerebellar disease, psychosis, coordination or movement disorder)\n* Contraindication to receive intrathecal methotrexate\n* Prior treatment with blinatumomab\n* Active malignancy other than ALL\n* Active infection or any other concurrent disease or medical condition that was deemed to interfere with the conduct of the study as judged by the investigator",{"count":52,"type":19},[54],"Changing the schedule of intrathecal chemotherapy to be given before and during blinatumomab will maintain the anti-leukemic effects of this drug while at the same time adding the benefit of limiting the neurotoxicity associated with cytokine release.",[115],"Acute Lymphoblastic Leukemia",{"date":81,"type":35},{"date":118,"type":35},"2023-06-30",{"date":120,"type":19},"2026-12-01",{"name":41,"class":42},{"id":123,"slug":4,"hasResults":10,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":10,"sex":15,"minAge":49,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":129,"phases":4,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":133,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":43},"100471368","NCT05417971","Reduced Intensity Fludarabine and TBI Prior to Haplo-Identical Transplantation","A Phase II Trial of Reduced Intensity Fludarabine and Total Body Irradiation-Based Conditioning Prior to Haplo-Identical Transplantation for Patients With Hematologic Malignancies","Inclusion Criteria:\n\n* Availability of 3\u002F6 - 5\u002F6 matched related donor with a negative HLA-cross match in the host vs. graft direction willing to donate peripheral blood stem cells\n* KPS \\>\u002F= 70%\n* Hematologic malignancy requiring allogeneic transplantation, with a predicted high risk of relapse following non-myeloablative, low intensity conditioning.\n\nExclusion Criteria:\n\n* Poor cardiac function (LVEF \\\u003C45%)\n* Poor pulmonary function (FEV, FVC, DLCO \\\u003C60%)\n* Poor liver function (bilirubin \\>\u002F= 2.5mg\u002FdL; AST or ALT \\>3xULN)\n* Poor renal function (creatinine clearance \\\u003C40mL\u002Fmin)\n* HIV-positive; active HepB or HepC\n* Uncontrolled infection\n* Pregnant female or not able to practice adequate contraception\n* Debilitating medical or psychiatric illness which would preclude their giving informed consent",{"count":52,"type":19},"OBSERVATIONAL","This trial will evaluate the safety and efficacy of RIC HIDT transplant protocol following fludarabine and intermediate-dose TBI 800 cGy utilizing PBSC as the stem cell source.",[132],"Hematologic Malignancy",{"date":62,"type":35},{"date":135,"type":35},"2022-08-29",{"date":137,"type":19},"2026-12-31",{"name":41,"class":42},{"id":140,"slug":4,"hasResults":10,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":10,"sex":15,"minAge":49,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":20,"phases":148,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":152,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":43},"100380748","NCT04237623","GM-CSF With Post-Transplant Cyclophosphamide","Phase II Trial Evaluating the Efficacy and Safety of Sargramostim Post-Infusion of T-Replete HLA Mismatched Peripheral Blood Haploidentical Hematopoietic Stem Cells and With Post Transplant Cyclophosphamide","Inclusion Criteria:\n\n* Availability of 5\u002F10 to 8\u002F10 matched related donor\n* KPS \\>\u002F= 70%\n* CML, AML, MDS, ALL, CLL, HD, NHL, MPS\u002FCMML, MM, any other hematologic condition deemed an eligible indication for allogeneic transplant by the treating center\n\nExclusion Criteria:\n\n* Poor cardiac, pulmonary, liver, and renal function\n* HIV-positive\n* Patients who have a debilitating medical or psychiatric illness that would preclude them from giving informed consent\n* History of severe or serious allergic reaction to human GM-CSF or yeast-derived products","78 Years",{"count":147,"type":19},38,[54],"Given the increased number of HLA-mismatched haploidentical transplantation with post-transplant cyclophosphamide performed each year and the high risk of infectious complications associated with this type of transplant, the investigators suggest that GM-CSF administration post-infusion of T-replete haploidentical stem cells and post-transplant cyclophosphamide can yield similar count recovery rates to G-CSF with a potential of lowering risk of infectious complications.",[151],"Transplant-Related Hematologic Malignancy",{"date":62,"type":35},{"date":154,"type":35},"2020-05-18",{"date":156,"type":19},"2026-09-18",{"name":41,"class":42},{"id":159,"slug":4,"hasResults":10,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":10,"sex":15,"minAge":164,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":20,"phases":167,"briefSummary":168,"conditions":169,"keywords":171,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":173,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":179},"100272624","NCT02828592","Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia","A Study of T-Cell Replete, HLA-Mismatched Haploidentical Bone Marrow Transplantation With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia Lacking HLA-Matched Related Donor","Inclusion Criteria:\n\n* Availability of 3\u002F6 - 5\u002F6 matched (HLA-A, B, DR) related donor who must have negative HLA cross-match in the host vs. graft direction\n* Age \\\u003C= 65 years for previously treated and \\\u003C= 75 years for previously treated patients\n* KPS \\>= 70%\n* Aplastic Anemia that meets the following criteria:\n\nPeripheral Blood (must fulfill 2 of 3):\n\n* \\\u003C500 PMN\u002Fmm3\n* \\\u003C20,000 platelets\n* absolute reticulocyte count \\\u003C40,000\u002FmicroL\n\nBone Marrow (must be either):\n\n* markedly hypocellular (\\\u003C25% of normal cellularity)\n* moderately hypocellular with 70% non-myeloid precursors and patient meets peripheral blood criteria above\n\nExclusion Criteria:\n\n* poor cardiac function (LVEF \\\u003C40%)\n* poor pulmonary function (FEV1 \\& FVC \\\u003C50% predicted)\n* poor liver function (bili \\>= 2mg\u002FdL)\n* poor renal function (creatinine \\>= 2.0mg\u002FdL or creatinine clearance \\\u003C40mL\u002Fmin)\n* prior allogeneic transplant","1 Year","75 Years",{"count":52,"type":19},[54],"Severe aplastic anemia is a rare and serious form of bone marrow failure related to an immune-mediated mechanism that results in severe pancytopenia and high risk for infections and bleeding. Patients with matched sibling donors for transplantation have a 80-90% chance of survival; however, a response rate with just immunosuppression for those patients lacking suitable HLA-matched related siblings is only 60%. With immunosuppression, only 1\u002F3 of patients are cured, 1\u002F3 are dependent on long term immunosuppression, and the other 1\u002F3 relapse or develop a clonal disorder. Recent studies have shown that using a haploidentical donor for transplantation has good response rates and significantly lower rates of acute and chronic GVHD.",[170],"Severe Aplastic Anemia",[172],"SAA",{"date":81,"type":35},{"date":175,"type":35},"2016-09-09",{"date":177,"type":19},"2028-08-31",{"name":41,"class":42},2,{"id":181,"slug":4,"hasResults":10,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":10,"sex":15,"minAge":49,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":20,"phases":188,"briefSummary":189,"conditions":190,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":43},"100632236","NCT07511062","Axatilimab Combined With Decitabine\u002FVenetoclax for the Treatment of TP53-mutated AML","Axatilimab Combined With Decitabine\u002FVenetoclax for the Treatment of TP53-mutated\u002FDeleted AML Patients","Inclusion Criteria:\n\n* MDS\u002FAML or AML with a TP53 mutation or deletion, defined as:\n* greater than or equal to 10% AND (one of the following):\n* presence of a TP53 mutation\n* presence of a TP53 deletion by FISH\n* positive TP53 staining on IHC of diagnostic bone marrow\n* Either untreated or first salvage (primary refractory or first relapse)\n\nExclusion Criteria:\n\n* KPS \\\u003C60\n* active uncontrolled infection\n* history of HIV or active HBV or HBC infection\n* currently active second malignancy\n* calculated CrCl \\\u003C40mL\u002Fmin\n* AST and\u002For ALT and\u002For direct bilirubin \\>3x ULN\n* cardiac ejection fraction \\\u003C40% or history of uncontrolled cardiac arrhythmias\n* history of acute or chronic pancreatitis, history of myositis\n* known leukemia involvement of CNS\n* hematopoietic stem cell transplantation within 3 months of treatment start and\u002For persistent non-hematologic toxicities of Grade 2+ related to the transplant\n* active acute or chronic GVHD requiring immunosuppressive treatment",{"count":187,"type":19},32,[22],"Axatilimab combined with Decitabine\u002FVenetoclax for the treatment of TP53-mutated\u002Fdeleted AML patients",[191,192],"Acute Myeloid Leukemia","TP53 Gene Mutation","2026-03-31",{"date":195,"type":35},"2026-04-06",{"date":197,"type":19},"2026-08-01",{"date":199,"type":19},"2030-08-01",{"name":41,"class":42},""]